Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
J Mol Diagn ; 22(7): 957-966, 2020 07.
Artigo em Inglês | MEDLINE | ID: mdl-32380172

RESUMO

Medulloblastoma (MB) is the most common malignant brain tumor in children. It is currently classified in four main molecular subgroups with different clinical outcomes: sonic hedgehog, wingless, group 3, and group 4 (MBSHH, MBWNT, MBGRP3, or MBGRP4). Presently, a 22-gene expression panel has been efficiently applied for molecular subgrouping using nCounter technology. In this study, formalin-fixed, paraffin-embedded samples from 164 Brazilian medulloblastomas were evaluated, applying the 22-gene panel, and subclassified into the low and high expression of nine key medulloblastoma-related genes. In addition, TP53 mutation status was assessed using TruSight Tumor 15 Panel, and its correlation with expression and prognostic impact was evaluated. Samples from 149 of 164 patients (90%) were classified into MBSHH (47.7%), MBWNT (16.1%), MBGRP3 (15.4%), and MBGRP4 (20.8%). GNAS presented the highest expression levels, with higher expression in MBSHH. TP53, MYCN, SOX2, and MET were also up-regulated in MBSHH, whereas PTEN was up-regulated in MBGRP4. GNAS, TP53, and PTEN low expression was associated with the unfavorable patient outcome only for MBSHH (P = 0.04, P = 0.01, and P = 0.02, respectively). TP53 mutations were detected in 28.57% of MBSHH cases and exhibited association with lower expression and worse clinical outcome, although not statistically significant. The 22-gene panel for molecular classification of medulloblastoma associated with the expression of GNAS, TP53, and PTEN improves the patient prognostication in MBSHH subgroup and can be easily incorporated in the 22-gene panel without any additional costs.


Assuntos
Neoplasias Cerebelares/classificação , Neoplasias Cerebelares/genética , Cromograninas/genética , Subunidades alfa Gs de Proteínas de Ligação ao GTP/genética , Proteínas Hedgehog/genética , Meduloblastoma/classificação , Meduloblastoma/genética , PTEN Fosfo-Hidrolase/genética , Transcriptoma , Proteína Supressora de Tumor p53/genética , Adolescente , Brasil/epidemiologia , Neoplasias Cerebelares/epidemiologia , Criança , Pré-Escolar , Estudos de Coortes , Análise Mutacional de DNA/métodos , Feminino , Sequenciamento de Nucleotídeos em Larga Escala/métodos , Humanos , Lactente , Masculino , Meduloblastoma/epidemiologia , Mutação , Prognóstico , Adulto Jovem
2.
Braz J Otorhinolaryngol ; 78(4): 59-65, 2012.
Artigo em Inglês, Português | MEDLINE | ID: mdl-22936138

RESUMO

UNLABELLED: Many studies have reported increased expression of S100 A7 (psoriasin) in neoplastic lesions. Among them are studies on breast carcinoma, bladder squamous cell carcinoma, skin tumors and oral cavity squamous cell carcinoma. The expression of S100 A7 has not been described for laryngeal cancer. OBJECTIVE: This study aims to identify the expression of the calcium-binding protein S100 A7 and its correlation with squamous cell carcinomas of the larynx. MATERIAL AND METHODS: Specimens from 63 patients were submitted to immunohistochemistry testing with antibody S100 A7. Results were classified and compared. RESULTS: The group with highly differentiated tumors had the highest treatment failure scores. Moderately differentiated tumors had higher treatment failure scores than poorly differentiated tumors. Higher scores were predominantly seen on stages I and II in moderately differentiated tumors, whereas score distribution was more homogeneous in advanced stage disease (III and IV). Regarding failure in treatment, the group scoring zero (3/4 complications: 75%) differed significantly from the remaining groups (13/59: 22%). CONCLUSIONS: S100 A7 marker was expressed in 93.7% of laryngeal cancer cases, with higher positive correlation rates in more differentiated tumors and significantly lower rates of treatment failure. Scores had no impact on survival rates.


Assuntos
Carcinoma de Células Escamosas/metabolismo , Neoplasias Laríngeas/metabolismo , Proteínas de Neoplasias/metabolismo , Proteínas S100/metabolismo , Adulto , Idoso , Biomarcadores Tumorais/análise , Biomarcadores Tumorais/metabolismo , Carcinoma de Células Escamosas/mortalidade , Carcinoma de Células Escamosas/patologia , Feminino , Humanos , Imuno-Histoquímica , Neoplasias Laríngeas/mortalidade , Neoplasias Laríngeas/patologia , Pessoa de Meia-Idade , Proteínas de Neoplasias/análise , Recidiva Local de Neoplasia , Estadiamento de Neoplasias , Proteína A7 Ligante de Cálcio S100 , Proteínas S100/análise , Análise de Sobrevida
3.
Braz. j. otorhinolaryngol. (Impr.) ; 78(4): 59-65, jul.-ago. 2012. ilus, tab
Artigo em Português | LILACS | ID: lil-646772

RESUMO

Muitos estudos relatam o aumento da expressão de S100 A7 (psoriasina) em lesões neoplásicas. Destacam-se trabalhos em carcinoma da mama, espinocelular da bexiga, pele e cavidade oral. Não foi demonstrada expressão da S100 A7 em câncer de laringe. OBJETIVO: Identificar a expressão da proteína ligadora de cálcio S100 A7 e sua correlação com carcinomas espinocelular da laringe. MATERIAL E MÉTODOS: Amostras de tecido neoplásico de 63 pacientes foram submetidos à imunohis toquímica com o anticorpo S110 A7. Os resultados foram classificados e comparados. RESULTADOS: O grupo bem diferenciado teve a maior pontuação de falha no tratamento. O grupo moderadamente diferenciado apresentou escores mais elevados do que o grupo pouco diferenciado. Pontuações mais altas predominaram nos estágios I e II no grupo moderadamente diferenciado, enquanto a distribuição do escore foi mais homogênea em estados avançados (III e IV). Em relação às falhas no tratamento, o grupo pontuação zero (04/03 complicações: 75%) diferiu significativamente da pontuação restante (13/59: 22%). CONCLUSÕES: A S100 A7 foi expressa em 93,7% dos casos de câncer de laringe, com maior positividade nos tumores mais diferenciados e taxa significativamente menor de falha no tratamento. A pontuação obtida não teve impacto sobre a sobrevivência.


Many studies have reported increased expression of S100 A7 (psoriasin) in neoplastic lesions. Among them are studies on breast carcinoma, bladder squamous cell carcinoma, skin tumors and oral cavity squamous cell carcinoma. The expression of S100 A7 has not been described for laryngeal cancer. OBJECTIVE: This study aims to identify the expression of the calcium-binding protein S100 A7 and its correlation with squamous cell carcinomas of the larynx. MATERIAL AND METHODS: Specimens from 63 patients were submitted to immunohistochemistry testing with antibody S100 A7. Results were classified and compared. RESULTS: The group with highly differentiated tumors had the highest treatment failure scores. Moderately differentiated tumors had higher treatment failure scores than poorly differentiated tumors. Higher scores were predominantly seen on stages I and II in moderately differentiated tumors, whereas score distribution was more homogeneous in advanced stage disease (III and IV). Regarding failure in treatment, the group scoring zero (3/4 complications: 75%) differed significantly from the remaining groups (13/59: 22%). CONCLUSIONS: S100 A7 marker was expressed in 93.7% of laryngeal cancer cases, with higher positive correlation rates in more differentiated tumors and significantly lower rates of treatment failure. Scores had no impact on survival rates.


Assuntos
Adulto , Idoso , Feminino , Humanos , Pessoa de Meia-Idade , Carcinoma de Células Escamosas/metabolismo , Neoplasias Laríngeas/metabolismo , Proteínas de Neoplasias/metabolismo , /metabolismo , Carcinoma de Células Escamosas/mortalidade , Carcinoma de Células Escamosas/patologia , Imuno-Histoquímica , Neoplasias Laríngeas/mortalidade , Neoplasias Laríngeas/patologia , Recidiva Local de Neoplasia , Estadiamento de Neoplasias , Proteínas de Neoplasias/análise , /análise , Análise de Sobrevida , Biomarcadores Tumorais/análise , Biomarcadores Tumorais/metabolismo
4.
J. epilepsy clin. neurophysiol ; 16(2): 59-63, 2010. tab
Artigo em Inglês | LILACS | ID: lil-558807

RESUMO

BACKGROUND AND PURPOSE: Rasmussen Encephalitis (RE) is characterized by intractable epilepsy, progressive hemiparesis and unilateral hemispheric atrophy. The progression of the symptoms usually occurs within months to few years. Antiepileptic drugs are usually not effective to control disease progression and epilepsy surgery in the form of hemispheric disconnection has been considered the treatment of choice. This work describes the clinical and electrographic analyses, as well as the post-operative evolution of patients with RE. PATIENTS AND METHODS: This work includes all the patients with RE evaluated from January 1995 to January 2008 by the Ribeirão Preto Epilepsy Surgery Program (CIREP) considering demographic data, interictal and ictal electroencephalographic (EEG) findings; anatomo-pathological findings and clinical outcome. RESULTS: Twenty-five patients were evaluated, thirteen were female. Mean age of epilepsy onset was 4.4±2.0 years. There were no differences between patients with slow and fast evolution with respect to age of epilepsy onset (p=0.79), age at surgery (p=0.24), duration of epilepsy (0.06), and follow-up (p=0.40). There were no correlations between the presence of bilateral EEG abnormalities or the absence of spikes and post-operative seizure outcome (p=0.06). Twenty-three patients underwent surgery. The mean follow-up was 75.3 months. Eleven patients had total seizure control. Twelve individuals persisted with seizures consisting of mild facial jerks (6 patients), occasional hemigeneralized tonic-clonic seizures (3 patients), and frequent tonic-clonic seizures (3 patients). Mental and language impairment was observed in 15 and 12 patients, after surgery, respectively. CONCLUSIONS: This retrospective study reported the clinical and electrographic analysis, as well as the evolution of 23 patients with RE. Fourteen patients achieved satisfactory seizure control, three patients had partial response to surgery, and five patients had maintenance of the pre-operative condition. All patients with left side involvement presented with some language and cognitive disturbance.


INTRODUÇÃO E OBJETIVOS: A Encefalite de Rasmussen (ER) é caracterizada por epilepsia intratável, hemiparesia progressiva e atrofia hemisférica unilateral. A progressão dos sintomas geralmente ocorre em meses ou poucos anos. As drogas antiepilépticas são usualmente ineficazes no controle da progressão da doença e o tratamento cirúrgico, com desconexão hemisférica tem sido considerado o tratamento de escolha. Neste trabalho descreveremos os achados clínicos e eletrográficos, assim como a evolução pós-operatória de pacientes com ER. PACIENTES E MÉTODOS: foram incluídos todos os pacientes com ER avaliados no período de janeiro de 1995 a janeiro de 2008, no Centro de Cirurgia de Epilepsia de Ribeirão Preto (CIREP), sendo considerados os dados demográficos, os achados do eletrencefalograma (EEG) interictal e ictal, resultado anatomo-patológico e o seguimento clínico. RESULTADOS: Vinte e cinco pacientes foram avaliados, 13 eram do sexo feminino. A idade média de início da epilepsia foi de 4.4±2.0 anos. Não houve diferenças significativas entre os pacientes com evolução lenta ou rápida considerando-se a idade de início da epilepsia (p=0,79), idade da cirurgia (p=0,24), duração da epilepsia (p=0,06) e tempo de seguimento (p=0,40). Não houve correlação entre a presença de alterações bilaterais ou ausência de descargas ao EEG e o seguimento pós-operatório (p=0,06). Vinte e três pacientes foram submetidos à cirurgia. O tempo médio de seguimento foi de 75,3 meses. Onze pacientes evoluíram com controle total das crises. Doze pacientes permaneceram com crises que consistiram de clonias faciais sutis (6 pacientes), crises tônico-clônicas hemigeneralizadas ocasionais (3 pacientes) ou crises tônico-clônicas frequentes (3 pacientes). Alterações cognitivas e de linguagem foram observadas em 15 e 12 pacientes após a cirurgia, respectivamente. CONCLUSÕES: este estudo retrospectivo relatou os achados clínicos, eletrográficos e a evolução de 23 pacientes. Controle satisfatório das crises foi obtido em 14 pacientes. Três pacientes tiveram resposta parcial com a cirurgia e cinco pacientes mantiveram o quadro pré-operatório. Todos os pacientes com envolvimento do hemisfério cerebral esquerdo evoluíram com distúrbio de linguagem e cognitivo.


Assuntos
Humanos , Feminino , Pediatria , Encefalite , Epilepsia/cirurgia
5.
Childs Nerv Syst ; 25(5): 583-9, 2009 May.
Artigo em Inglês | MEDLINE | ID: mdl-19153752

RESUMO

BACKGROUND AND PURPOSE: Rasmussen encephalitis (RE) is characterized by intractable epilepsy, progressive hemiparesis, and unilateral hemispheric atrophy. The progression of the symptoms to significant neurological impairment usually occurs within months to a few years. RE causes are unknown, although evidence of an autoimmune process has been extensively described in the literature. Antiepileptic drugs are usually not effective to control seizures or cerebral atrophy; despite data supporting a beneficial effect of early immunosuppressive and immunomodulatory interventions, for intractable seizures in RE patients with advanced disease, epilepsy surgery in the form of hemispheric disconnection has been considered the treatment of choice. This work describes the clinical and electrographic analyses, as well as the post-operative evolution of patients with RE. MATERIALS AND METHODS: This work includes all the patients with RE evaluated from January 1995 to January 2008 by the Ribeirão Preto Epilepsy Surgery Program (CIREP), taking variables such as gender; age at epilepsy onset; seizure semiology; seizure frequency; interictal and ictal electroencephalographic (EEG) findings; age at surgery, when done; duration of epilepsy; surgery complications; follow-up duration; anatomo-pathological findings; post-surgery seizure; language and cognitive outcome; and anti-epileptic drug treatment after surgery into account. RESULTS: Twenty-five patients were evaluated; thirteen were female. Mean age of epilepsy onset was 4.4+/-2.0 years. There were no differences between patients with slow and fast evolution with respect to age of epilepsy onset (p=0.79), age at surgery (p=0.24), duration of epilepsy (0.06), and follow-up (p=0.40). There were no correlations between the presence of bilateral EEG abnormalities or the absence of spikes and post-operative seizure outcome (p=0.06). Immunomodulatory therapy was tried in 12 patients (48%). Twenty-three patients underwent surgery. The mean follow-up was 63.3 months. Eleven patients had total seizure control. Twelve individuals persisted with seizures consisting of mild facial jerks (six patients), occasional hemigeneralized tonic-clonic seizures (three patients), and frequent tonic-clonic seizures (three patients). Mental and language impairment was observed in 15 and 12 patients, after surgery, respectively. Eight patients presented post-operative cognitive decline, while only two patients had cognitive improvement. Comparing pre- and post-operative language deficits, 66.7% of the 12 patients with language disturbance did not improve after surgery. CONCLUSIONS: This retrospective study reported the clinical and electrographic analysis, as well as the evolution of 23 patients with RE. Patients were divided into two groups: fast evolution and slow evolution to hemiparesis and epilepsia partialis continua. These groups may represent different RE substrates. Fourteen patients achieved satisfactory seizure control, three patients had partial response to surgery, and five patients had maintenance of the pre-operative condition. All patients with left-side involvement presented with some language disturbance, which did not improve after surgery in 66.6% of patients. Cognitive evaluation showed that the majority of the patients did not have any significant improvement, and 38.1% had cognitive deterioration after surgery.


Assuntos
Cognição , Encefalite/cirurgia , Idioma , Procedimentos Neurocirúrgicos/efeitos adversos , Paresia/terapia , Convulsões/terapia , Adolescente , Fatores Etários , Anticonvulsivantes/uso terapêutico , Criança , Pré-Escolar , Eletroencefalografia , Encefalite/complicações , Encefalite/tratamento farmacológico , Encefalite/fisiopatologia , Feminino , Seguimentos , Humanos , Masculino , Testes Neuropsicológicos , Paresia/etiologia , Estudos Retrospectivos , Convulsões/etiologia , Fatores Sexuais , Fatores de Tempo , Falha de Tratamento , Resultado do Tratamento
6.
Appl Physiol Nutr Metab ; 31(5): 490-4, 2006 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17111002

RESUMO

Myopathy is a well-known side effect of corticosteroid therapy. Creatine monohydrate (Cr) supplementation has been shown to increase fat-free mass and muscular function. This study aimed to investigate if Cr administration could offset the deleterious functional effects of high doses of steroids. Fifty-six male Syrian golden hamsters were randomized among 4 groups: GI (n = 10), subcutaneous (s.c.) and intraperitoneal (i.p.) saline; GII (n = 10), s.c. saline and i.p. Cr (600 mg.kg(-1).d(-1)); GIII (n = 18), s.c. dexamethasone (7.5 mg.kg(-1).d(-1)) and i.p. saline; and GIV (n = 18), s.c. dexamethasone and i.p. Cr. Daily voluntary running was measured using activity wheels for 18 d. At the end of the study, statistically significant differences in running were observed between all groups, except for GI versus GII (GI, 8878 +/- 2737 m; GII, 9145 +/- 2000 m; GIII, 4289 +/- 2623 m; GIV, 6339 +/- 2345 m). Dexamethasone led to a significant decrease in cross-sectional area of type II fibers of the medial gastrocnemius. The cross-sectional area of type I fibers was significantly larger in GIV than in GIII. In conclusion, Cr administration attenuated the impairment of daily spontaneous running of hamsters receiving a high dose of corticosteroids. Additional research is needed to clarify the clinical implications of this finding.


Assuntos
Corticosteroides/efeitos adversos , Creatina/administração & dosagem , Doenças Musculares/induzido quimicamente , Doenças Musculares/prevenção & controle , Corrida , Corticosteroides/administração & dosagem , Animais , Cricetinae , Dexametasona/administração & dosagem , Dexametasona/efeitos adversos , Histocitoquímica , Masculino , Mesocricetus , Fibras Musculares de Contração Rápida/patologia , Músculo Esquelético/patologia , Doenças Musculares/patologia
7.
Seizure ; 15(6): 420-7, 2006 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16787751

RESUMO

Neocortical development is a highly complex process encompassing cellular proliferation, neuronal migration and cortical organization. At any time this process can be interrupted or modified by genetic or acquired factors causing malformations of cortical development (MCD). Epileptic seizures are the most common type of clinical manifestation, besides developmental delay and focal neurological deficits. Seizures due to MCD are frequently pharmacoresistant, especially those associated to focal cortical dysplasia (FCD). Surgical therapy results have been reported since 1971, however, currently available data from surgical series are still limited, mainly due to small number of patients, distinct selection of candidates and surgical strategies, variable pathological diagnosis and inadequate follow-up. This study addresses the possibilities of seizure relief following resection of focal cortical dysplasia, and the impact of presurgical evaluation, extent of resection and pathological findings on surgical outcome. We included 41 patients, 22 adults and 19 children and adolescents, with medically intractable seizures operated on from 1996 to 2002. All were submitted to standardized presurgical evaluation including high-resolution MRI, Video-EEG monitoring and ictal SPECT. Post-surgical seizure outcome was classified according to Engel's schema. Univariate and multivariate analysis were performed. Fifteen patients had temporal and 26 extratemporal epilepsies. Of the total 26 patients (63.4%) reached seizure-free status post-operatively. There was no correlation between outcome and age at surgery, duration of epilepsy, frequency of seizures, and pathological findings. There was, however, a clear correlation with topography of FCD (temporal versus extratemporal) and regional ictal EEG onset, on univariate as well as multivariate analysis.


Assuntos
Córtex Cerebral/anormalidades , Córtex Cerebral/cirurgia , Epilepsia/cirurgia , Adolescente , Adulto , Córtex Cerebral/patologia , Criança , Eletrodos Implantados , Eletroencefalografia , Epilepsia/congênito , Humanos , Análise Multivariada , Complicações Pós-Operatórias , Cuidados Pré-Operatórios , Prognóstico , Convulsões/cirurgia , Tomografia Computadorizada de Emissão de Fóton Único , Resultado do Tratamento , Gravação em Vídeo
8.
Epilepsia ; 46(9): 1442-9, 2005 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16146440

RESUMO

PURPOSE: Posterior cortex epilepsies (PCEs) encompass a group of epilepsies originating from the occipital, parietal, or occipital border of the temporal lobe, or from any combination of these regions. When their seizures are refractory to pharmacologic treatment, these patients are usually referred for surgery. The aim of our study was to analyze clinical characteristics of all PCE patients referred for surgery from 1994 to 2003, and to search for predictors of surgical outcome. METHODS: We performed a retrospective analysis of clinical and laboratory data from 81 consecutive refractory PCE patients referred for surgery. Surgical and nonsurgical groups of patients were compared, and detailed analyses of all variables of the surgical cases were performed in the search for predictors of seizure outcome. RESULTS: Risk factors for PCEs included gliosis (34.56%), malformations of cortical development (33.33%), tumors (8.64%), brain trauma (3.70%), Sturge-Weber disease (4.93%), vascular malformations (3.70%), family history of epilepsy (3.70%), history of CNS infections (2.46%), and low IQ (2.46%). Of the 81 patients, 44 were submitted to surgery at the time of the completion of this study. Surgical treatment was highly effective in improving seizures (p<0.001) when compared with previous pharmacologic treatment alone. Twenty-eight (65.11%) patients became seizure free after surgery versus none in the nonsurgical group. Regarding outcome predictors, patients with shorter duration of epilepsy and those without neurologic abnormalities on clinical examination had higher chances of favorable evolution. CONCLUSIONS: Surgical treatment is effective for the treatment of PCEs and superior to pharmacologic therapy alone. In our series, shorter duration of epilepsy and normal neurologic examination were the only independent variables that predicted better surgical outcome.


Assuntos
Córtex Cerebral/fisiopatologia , Epilepsia/diagnóstico , Adulto , Córtex Cerebral/cirurgia , Eletroencefalografia/estatística & dados numéricos , Epilepsias Parciais/diagnóstico , Epilepsias Parciais/fisiopatologia , Epilepsias Parciais/cirurgia , Epilepsia/fisiopatologia , Epilepsia/cirurgia , Epilepsia do Lobo Temporal/diagnóstico , Epilepsia do Lobo Temporal/fisiopatologia , Epilepsia do Lobo Temporal/cirurgia , Feminino , Humanos , Imageamento por Ressonância Magnética , Masculino , Lobo Parietal/fisiopatologia , Lobo Parietal/cirurgia , Prognóstico , Fatores de Risco , Resultado do Tratamento , Gravação de Videoteipe
9.
Acta cir. bras ; 15(supl.2): 39-42, 2000. tab, graf
Artigo em Português | LILACS | ID: lil-282429

RESUMO

Fez-se um estudo imunohistoquímico do antígeno nuclear de proliferação celular (PCNA) em 26 adenomas e 24 carcinomas de adrenal através da técnica da avidina-biotina-peroxidase. O índice de marcação (IP) do PCNA, definido com o número de células marcadas/1000 contadas, foi em média de 77,4 +/- 66,1 (mediana - 63,5) para os adenomas enquanto que para os carcinomas foi 215,8 +/- 56,0 (mediana - 217,5) (p<0,0001). Estabelecendo-se o IP de 100 o marcador (para a discriminação de carcinomas dos adenomas) o marcador exibiu sensibilidade, especificidade e valor preditivo positivo seguintes, respectivamente: 100 por cento, 69 por cento e 75 por cento.


Assuntos
Humanos , Masculino , Feminino , Adenoma , Neoplasias do Córtex Suprarrenal , Carcinoma Adrenocortical/epidemiologia , Antígeno Nuclear de Célula em Proliferação , Adrenalectomia , Imuno-Histoquímica , Índice Mitótico/métodos
10.
Rev. Soc. Bras. Med. Trop ; 28(3): 185-93, jul.-set. 1995. ilus, tab
Artigo em Português | LILACS | ID: lil-163733

RESUMO

Com o objetivo de se conhecer a prevalência da infecçao por leishmaniose tegumentar americana, e caracterizaçao da populaçao atingida, em área de transmissao recente, na localidade de Boa Sorte, município de Corguinho, MS, procedeu-se ao estudo, no período de março/9l a março/94, da populaçao residente, compreendendo 150 habitantes. Destes, 12 apresentavam lesoes suspeitas de leishmaniose tegumentar. Em 8 deles foi possível a confirmaçao por meio de exames parasitológicos. Apenas um paciente apresentou a forma mucosa, os demais manifestaram as formas cutâneas, sendo: ulcerada (3), úlcero-verrucosa (1), úlcero vegetante (1), placa-infiltrada (1) e lesao nodular com exuberante adenopatia regional (1). Os pacientes responderam bem ao tratamento com antimoniato de N-metilglucamina (glucantime), 10 a 2Omg Sbv/kg/dia durante 20 dias, com cicatrizaçao das lesoes e raros efeitos colaterais. O parasito isolado de todos os pacientes foi identificado como Leishmania (Viannia) braziliensis, através de anticorpos monoclonais. O teste de Montenegro aplicado em 150 moradores revelou 32 reagentes. Destes, 6 eram portadores da doença, 21 mostraram seqüelas sugestivas da parasitose e 5 nao apresentaram sinais da infecçao. A faixa etária atingida pela parasitose compreendia de 22 a 78 anos com predomínio de homens (75 por cento). A transmissao até o momento revelou-se de caráter extradomiciliar.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Leishmaniose Cutânea/epidemiologia , Brasil/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...